Top 10 Reasons Why Choose Snibe

》No.1 CLIA manufacturer in China

》23 years focus on immunoassay and IVD
》Reliable and stable ISO quality management system CHEMILUMINESCENCE
》Powerful and flexible platform with dedicated assays
IMMUNOASSAY
》1st in China who received FDA Cleared on CLIA product
FOCUSED MANUFACTURER
》More than 8000 end users in more than 130 countries and areas
》Fast responding to market feedback and timely launching of new assays
》Original manufacturer of core products including analyzers and reagents
》Advanced magnetic microbeads separation and ABEI labeling technology
》Quality guarantee by the third party quality control and External Quality Assessment (EQA)

Beijing

Shanghai

Guangzhou

Shenzhen
M1009E171222

www.snibe.com
 In-Vitro
Contents Diagnostics
In-Vitro Diagnostic Market Size
Compound Annual Growth Rate(CAGR) of over 5%

Company Profile / 03
Integrated System / 05
Immunoassay / 07
Biochemistry / 13 Rank
Third-party Quality Control / 15 POCT: 29%
Production / 17 Immunoassay: 26%
Comparison / 20
Clinical Chemistry: 14% POCT: 29%
Publication  / 3
Immunoassay: 26%
Microbiology: 12%

Hematology: 6%

Histology/Cytology: 4%

Blood Test: 3%

Nucleic Acid Assays: 2%

Flow Cytometry: 2%

Coagulation: 2%

Snibe International Business Growth Annual New Installation Unit

CAGR: 47.24%
CAGR: 67.18%

2012 2013 2014 2012

2015 2016 2013 2014
2017 2015 2016 2017

Snibe’s core products were put into batch production in 2010 and since then,
New Headquarters in 2019 the company has experienced rapid growth and development.
 In-Vitro
Contents Diagnostics
In-Vitro Diagnostic Market Size
Compound Annual Growth Rate(CAGR) of over 5%

Company Profile / 03
Integrated System / 05
Immunoassay / 07
Biochemistry / 13 Rank
Third-party Quality Control / 15 POCT: 29%
Production / 17 Immunoassay: 26%
Comparison / 20
Clinical Chemistry: 14% POCT: 29%
Publication  / 3
Immunoassay: 26%
Microbiology: 12%

Hematology: 6%

Histology/Cytology: 4%

Blood Test: 3%

Nucleic Acid Assays: 2%

Flow Cytometry: 2%

Coagulation: 2%

Snibe International Business Growth Annual New Installation Unit

CAGR: 47.24%
CAGR: 67.18%

2012 2013 2014 2012

2015 2016 2013 2014
2017 2015 2016 2017

Snibe’s core products were put into batch production in 2010 and since then,
New Headquarters in 2019 the company has experienced rapid growth and development.
Company
Profile
Shenzhen New Industries Biomedical Engineering Co., Ltd (Snibe) is located in the Hi-Tech Industrial Park of the
Nanshan District in Shenzhen, China.
Founded in December 1995, Snibe is a professional bio-medical company that specializes in the research, production
and sale of clinical laboratory instruments and in vitro reagents.
Since 1995, Snibe has been focusing on the R&D of immunoassay products and has developed the key technique of
utilising magnetic microbeads. After decades of effort, in 2008, Snibe became the first company in China to
successfully develop and release a fully automated Chemiluminescence Immunoassay (CLIA) System.

As a leading brand in China, Snibe is characterized by the following features:

• Application of advanced magnetic microbeads as the key separation material for its CLIA system
• Application of advanced synthesized small-molecule organic compounds as markers
• Developing and producing automated Chemiluminescence Immunoassay Systems

1995 Founded in Shenzhen, China

1997 Developed enzyme-linked immunoassay system-Magimuzyme

2002 Received "Shenzhen High-tech Enterprise" award

Developed semi-auto CLIA analyzer and dedicated reagent kits.

2005
Received "Shenzhen Science and Technology Progress Award"

ISO 9001, ISO 13485 certified by TUV

2007
Joined "National High-tech Industrialization Demonstration Project"

2008 Developed China's first automated CLIA analyzer and dedicated kits

2009 Received "National High-tech Enterprise" award

2010 Launched automated CLIA analyzer and dedicated kits

2012 Developed China's first Integrated System

2013 Launched high throughput CLIA analyzer MAGLUMITM 4000

2014 New Production Center and Headquarters put into use

2015 The new headquarters in Pingshan starts construction

2016 Launched CLIA analyzer MAGLUMITM 4000 Plus

2017 1st CLIA manufacturer in China who gets FDA cleared


Company
Profile
Shenzhen New Industries Biomedical Engineering Co., Ltd (Snibe) is located in the Hi-Tech Industrial Park of the
Nanshan District in Shenzhen, China.
Founded in December 1995, Snibe is a professional bio-medical company that specializes in the research, production
and sale of clinical laboratory instruments and in vitro reagents.
Since 1995, Snibe has been focusing on the R&D of immunoassay products and has developed the key technique of
utilising magnetic microbeads. After decades of effort, in 2008, Snibe became the first company in China to
successfully develop and release a fully automated Chemiluminescence Immunoassay (CLIA) System.

As a leading brand in China, Snibe is characterized by the following features:

• Application of advanced magnetic microbeads as the key separation material for its CLIA system
• Application of advanced synthesized small-molecule organic compounds as markers
• Developing and producing automated Chemiluminescence Immunoassay Systems

1995 Founded in Shenzhen, China

1997 Developed enzyme-linked immunoassay system-Magimuzyme

2002 Received "Shenzhen High-tech Enterprise" award

Developed semi-auto CLIA analyzer and dedicated reagent kits.

2005
Received "Shenzhen Science and Technology Progress Award"

ISO 9001, ISO 13485 certified by TUV

2007
Joined "National High-tech Industrialization Demonstration Project"

2008 Developed China's first automated CLIA analyzer and dedicated kits

2009 Received "National High-tech Enterprise" award

2010 Launched automated CLIA analyzer and dedicated kits

2012 Developed China's first Integrated System

2013 Launched high throughput CLIA analyzer MAGLUMITM 4000

2014 New Production Center and Headquarters put into use

2015 The new headquarters in Pingshan starts construction

2016 Launched CLIA analyzer MAGLUMITM 4000 Plus

2017 1st CLIA manufacturer in China who gets FDA cleared


 Integrated
System

BiolumiTM 8000

Flexible combination of different module

B+S I+B+S I+I+B+S I+B+B+B+E+S

Specificity

IMMUNOASSAY MODULE (I)
》 Magnetic separation, flash CLIA technology
》 More than 120 parameters(Tumor marker, Fertility,)
Hepatic Fibrosis, Inflammation Monitoring,
Cardiac Markers etc.)
》 25 reagents on board
》 280 tests/hour
》 Clot detection,liquid level detection
BIOCHEMISTRY MODULE (B)
》 1600 tests/hour
》 Continuous loading reagent during operation
》 Clot detection, liquid level detection
》 Wavelength range 340nm - 800nm,
detect 16 different wavelengths simultaneously
ELECTROLYTE MODULE(E)
》 1000 tests/hour
》Continuous loading reagent during operation
》 Clot detection, liquid level detection
SAMPLE PROCESSNG MODULE(S)
》 Loading 280 samples at one time
》 Recognize the barcode of primary tube
》 Continuous loading and unloading samples
during operation
》 Specific STAT channel


 Immunoassay
FDA
510(k)
Cleared

FDA
510(k)
Cleared

MAGLUMITM 600 MAGLUMITM 800 MAGLUMITM 1000 MAGLUMITM 2000 MAGLUMITM 2000 Plus MAGLUMITM 4000 Plus

SPECIFICATION SPECIFICATION SPECIFICATION SPECIFICATION SPECIFICATION SPECIFICATION

》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 16
samples
》 Reagent position: 4
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 40
samples
》 Reagent position: 9
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 120 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 15
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 15
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 25
》 Random access or batch mode, STAT
》 Refrigerated sample and reagent area
》 Throughput:
Maximum 280 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 25
》 Random access or batch mode, STAT
》 Refrigerated sample and reagent area

TARGETED END-USER TARGETED END-USER TARGETED END-USER TARGETED END-USER TARGETED END-USER TARGETED END-USER
》Small labs 》Small labs 》Mid-size Labs 》Mid or large size labs 》Large labs 》Large labs
》Back-up 》Mid-size Labs 》Hospitals 》Hospitals 》Hospitals 》Hospitals
》Chain labs 》Chain labs

TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY
》Daily test: 10-35 》5-10 parameters 》10-20 parameters 》> 20 parameters 》> 20 parameters 》> 20 parameters
》Daily test: 40-80 》Daily test: 50-100 》Daily test: 100-300 》Daily test: 100-300 》Daily test: 200-500


 Immunoassay
FDA
510(k)
Cleared

FDA
510(k)
Cleared

MAGLUMITM 600 MAGLUMITM 800 MAGLUMITM 1000 MAGLUMITM 2000 MAGLUMITM 2000 Plus MAGLUMITM 4000 Plus

SPECIFICATION SPECIFICATION SPECIFICATION SPECIFICATION SPECIFICATION SPECIFICATION

》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 16
samples
》 Reagent position: 4
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 40
samples
》 Reagent position: 9
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 120 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 15
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 15
》 Random access or batch
mode, STAT
》 Throughput:
Maximum 180 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 25
》 Random access or batch mode, STAT
》 Refrigerated sample and reagent area
》 Throughput:
Maximum 280 tests/hour
》 Sample and reagent continuous
loading
》 On board capability: up to 144
samples
》 Reagent position: 25
》 Random access or batch mode, STAT
》 Refrigerated sample and reagent area

TARGETED END-USER TARGETED END-USER TARGETED END-USER TARGETED END-USER TARGETED END-USER TARGETED END-USER
》Small labs 》Small labs 》Mid-size Labs 》Mid or large size labs 》Large labs 》Large labs
》Back-up 》Mid-size Labs 》Hospitals 》Hospitals 》Hospitals 》Hospitals
》Chain labs 》Chain labs

TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY TEST VOLUME PER DAY
》Daily test: 10-35 》5-10 parameters 》10-20 parameters 》> 20 parameters 》> 20 parameters 》> 20 parameters
》Daily test: 40-80 》Daily test: 50-100 》Daily test: 100-300 》Daily test: 100-300 》Daily test: 200-500


MAGLUMITM
Immunoassay
Thyroid Fertility Tumor Markers Cardiac TORCH EBV
TSH (3rd Generation) FSH Ferritin &.0% Toxo lgG EBV EA lgG
T4 LH AFP Troponin I 7R[ROJ0 EBV EA lgA
T3 +&*ȕ±+&* CEA 0\RJORELQ Rubella lgG EBV VCA lgG
FT4 PRL Total PSA NT-proBNP 5XEHOODOJ0 (%99&$OJ0
FT3 Estradiol f-PSA Aldosterone &09OJ* EBV VCA lgA
Tg (Thyroglobulin) Progesterone CA 125 Angiotensin I &09OJ0 EBV NA lgG
TGA (Anti-Tg) Testosterone CA 15-3 Angiotensin II HSV-1/2 lgG *EBV NA IgA
TRAb DHEA-S CA 19-9 D-Dimer +69OJ0
70$ free Testosterone +&*ȕ+&* LP-PLA2 HSV-2 lgG
free Estriol Tg (Thyroglobulin) +69,J0 Anemia
Anti-TPO hs-cTnl
Rev T3 17-OH Progesterone PAP hs-CRP *HSV-1 IgG Vitamin B12
Intact PTH $0+ CA 50 Direct Renin +69,J0 Ferritin
*SHBG CYFRA 21-1 *H-FABP Folate (FA)
*Androstenedione CA 242 *BNP
*PLGF CA 72-4 Infectious Disease
*sFLT-1 NSE Hepatic Fibrosis
Autoimmune Prenatal Screening HBsAg
S-100
Anti-HBs HA
TGA(Anti-Tg) SCCA AFP (Prenatal Screening) HBeAg PIIIP N-P
TRAb TPA-snibe IUHHȕ±+&*
Glyco Metabolism Anti-HBe C IV
70$ Pepsinogen I PAPP-A Anti-HBc Laminin
Anti-TPO C-Peptide Pepsinogen II +&*ȕ±+&* Anti-HCV Cholyglycine
ICA Insulin Gastrin-17 free Estriol Syphilis
IAA(Anti Insulin) ICA H.pylori IgG
Chagas
GAD 65 IAA (Anti Insulin) ȕ0* Drug Monitoring
Immunoglobulin HTLV I/II
Anti-IA2 Proinsulin Calcitonin
Anti-HAV CSA (Cyclosporine A)
*Anti-CCP GAD 65 Proinsulin OJ0 +$9,J0 FK 506 (Tacrolimus)
*Anti-dsDNA Anti-IA2 *H.pylori IgA lgA HIV p24 Ag Digoxin
*ANA +S\ORUL,J0 lgE HIV Ab/Ag combi
*ENA *proGRP lgG H.pylori IgG
*Anti-Sm *AFP-L3 Others
Bone Metabolism *H.pylori IgA
*Anti-Ribosomal-P *HE4
Inflammation Monitoring +S\ORUL,J0 GH (hGH)
*Anti-Scl-70 Calcitonin *PIVKA-II
$QWL+%F,J0 IGF-I
*Anti-CENP-B Osteocalcin *HER-2 hs-CRP
*Anti-Jo-1 PCT (Procalcitonin) Cortisol
25-OH Vitamin D
$QWL0 Intact PTH Kidney Function *IL- 6 ACTH
*Anti-Histone *IGFBP-3
ȕ&7;
*Anti-RNP ȕ20*
*PINP
*Anti-SSB Albumin Special assays
*Anti-SSA Routine assays
* Available soon
Product availability subject to required regulatory approval


MAGLUMITM
Immunoassay
Thyroid Fertility Tumor Markers Cardiac TORCH EBV
TSH (3rd Generation) FSH Ferritin &.0% Toxo lgG EBV EA lgG
T4 LH AFP Troponin I 7R[ROJ0 EBV EA lgA
T3 +&*ȕ±+&* CEA 0\RJORELQ Rubella lgG EBV VCA lgG
FT4 PRL Total PSA NT-proBNP 5XEHOODOJ0 (%99&$OJ0
FT3 Estradiol f-PSA Aldosterone &09OJ* EBV VCA lgA
Tg (Thyroglobulin) Progesterone CA 125 Angiotensin I &09OJ0 EBV NA lgG
TGA (Anti-Tg) Testosterone CA 15-3 Angiotensin II HSV-1/2 lgG *EBV NA IgA
TRAb DHEA-S CA 19-9 D-Dimer +69OJ0
70$ free Testosterone +&*ȕ+&* LP-PLA2 HSV-2 lgG
free Estriol Tg (Thyroglobulin) +69,J0 Anemia
Anti-TPO hs-cTnl
Rev T3 17-OH Progesterone PAP hs-CRP *HSV-1 IgG Vitamin B12
Intact PTH $0+ CA 50 Direct Renin +69,J0 Ferritin
*SHBG CYFRA 21-1 *H-FABP Folate (FA)
*Androstenedione CA 242 *BNP
*PLGF CA 72-4 Infectious Disease
*sFLT-1 NSE Hepatic Fibrosis
Autoimmune Prenatal Screening HBsAg
S-100
Anti-HBs HA
TGA(Anti-Tg) SCCA AFP (Prenatal Screening) HBeAg PIIIP N-P
TRAb TPA-snibe IUHHȕ±+&*
Glyco Metabolism Anti-HBe C IV
70$ Pepsinogen I PAPP-A Anti-HBc Laminin
Anti-TPO C-Peptide Pepsinogen II +&*ȕ±+&* Anti-HCV Cholyglycine
ICA Insulin Gastrin-17 free Estriol Syphilis
IAA(Anti Insulin) ICA H.pylori IgG
Chagas
GAD 65 IAA (Anti Insulin) ȕ0* Drug Monitoring
Immunoglobulin HTLV I/II
Anti-IA2 Proinsulin Calcitonin
Anti-HAV CSA (Cyclosporine A)
*Anti-CCP GAD 65 Proinsulin OJ0 +$9,J0 FK 506 (Tacrolimus)
*Anti-dsDNA Anti-IA2 *H.pylori IgA lgA HIV p24 Ag Digoxin
*ANA +S\ORUL,J0 lgE HIV Ab/Ag combi
*ENA *proGRP lgG H.pylori IgG
*Anti-Sm *AFP-L3 Others
Bone Metabolism *H.pylori IgA
*Anti-Ribosomal-P *HE4
Inflammation Monitoring +S\ORUL,J0 GH (hGH)
*Anti-Scl-70 Calcitonin *PIVKA-II
$QWL+%F,J0 IGF-I
*Anti-CENP-B Osteocalcin *HER-2 hs-CRP
*Anti-Jo-1 PCT (Procalcitonin) Cortisol
25-OH Vitamin D
$QWL0 Intact PTH Kidney Function *IL- 6 ACTH
*Anti-Histone *IGFBP-3
ȕ&7;
*Anti-RNP ȕ20*
*PINP
*Anti-SSB Albumin Special assays
*Anti-SSA Routine assays
* Available soon
Product availability subject to required regulatory approval


 Key
Techniques Principle
Chemiluminescence Immunoassay (CLIA) System ONE STEP ASSAY TWO STEP ASSAY
CLIA uses two important technologies, one is the labelling technology which determines the reaction mode, and the
other is a separation technology which determines the sensitivity, accuracy and precision of the reagents.

LABELLING TECHNOLOGY SEPARATION TECHNOLOGY

Magnetic Sample,control,
Two types of labelling technologies are commonly MAGLUMITM uses Nano Magnetic Microbeads. As Sample,control,
or calibarator
Microbeads or calibarator

used. One is an enzyme label and another is a
non-enzyme small molecule.Enzyme label reagents are
not very stable and are easily affected by the change of
storage conditions.
The MAGLUMITM system applies ABEI labels. ABEI is a
non-enzyme small molecule with special molecular
formula to enhance stability in acid and alkaline
buffer.Using fast Chemiluminescence, ABEI's chemical
reaction with sodium hydroxide (NaOH) and Hyperoxide
(H2O2) finishes the process in 3 seconds.
separation technology, it has been widely used in the
field of CLIA.
Compared with traditional separation technology, it has
the following advantages:
》 Shortening the reaction time by enlarging the
reaction area of antigens and antibodies.
》 Enhancing the sensitivity by better and faster capture
of antigens and antibodies, 37°C 15 min 37°C 10 min
》 Reducing inter or intra-assay discrepancies
significantly by mixing the reagents thoroughly in a
liquid separation platform.
》 Enhancing the accuracy by absorbing antigens and
antibodies through chemical reaction.

Key technology Key technology

Luminescence label -- ABEI Magnetic microbeads

37°C 10 min
Luminesce for 3 seconds

Add Starter1 & Starter2

NOTE

Product Advantages:
》 Comprehensive test menu, over 154 parameters
》 High throughput, up to 280 tests/hour
》 Reliable performance, lower breakdown rate
》 Same reagent package available for series instruments Luminesce for 3 seconds
》 Integrated reagent kit, internal control and
calibrators FOC
》 Easy to maintain and has worldwide service


 Key
Techniques Principle
Chemiluminescence Immunoassay (CLIA) System ONE STEP ASSAY TWO STEP ASSAY
CLIA uses two important technologies, one is the labelling technology which determines the reaction mode, and the
other is a separation technology which determines the sensitivity, accuracy and precision of the reagents.

LABELLING TECHNOLOGY SEPARATION TECHNOLOGY

Magnetic Sample,control,
Two types of labelling technologies are commonly MAGLUMITM uses Nano Magnetic Microbeads. As Sample,control,
or calibarator
Microbeads or calibarator

used. One is an enzyme label and another is a
non-enzyme small molecule.Enzyme label reagents are
not very stable and are easily affected by the change of
storage conditions.
The MAGLUMITM system applies ABEI labels. ABEI is a
non-enzyme small molecule with special molecular
formula to enhance stability in acid and alkaline
buffer.Using fast Chemiluminescence, ABEI's chemical
reaction with sodium hydroxide (NaOH) and Hyperoxide
(H2O2) finishes the process in 3 seconds.
separation technology, it has been widely used in the
field of CLIA.
Compared with traditional separation technology, it has
the following advantages:
》 Shortening the reaction time by enlarging the
reaction area of antigens and antibodies.
》 Enhancing the sensitivity by better and faster capture
of antigens and antibodies, 37°C 15 min 37°C 10 min
》 Reducing inter or intra-assay discrepancies
significantly by mixing the reagents thoroughly in a
liquid separation platform.
》 Enhancing the accuracy by absorbing antigens and
antibodies through chemical reaction.

Key technology Key technology

Luminescence label -- ABEI Magnetic microbeads

37°C 10 min
Luminesce for 3 seconds

Add Starter1 & Starter2

NOTE

Product Advantages:
》 Comprehensive test menu, over 154 parameters
》 High throughput, up to 280 tests/hour
》 Reliable performance, lower breakdown rate
》 Same reagent package available for series instruments Luminesce for 3 seconds
》 Integrated reagent kit, internal control and
calibrators FOC
》 Easy to maintain and has worldwide service


 Biochemistry Biochemistry
Test Menu Analyzer
SPECIFICATION

CK TBA HDL-C *ASO

&.0% ALT (SGPT) LDL-C *RF
BiossaysTM 240
Į+%'+ AST (SGOT) TC *CRP )XOO5DQJH
》7KURXJKSXW240 tests/hour
LDH ALP TG *UIBC
》6DPSOH+DQGOLQJXSWR90 sample positions, STAT
*LDH1 GGT ApoE *Urine/CSF Protein
》5HDJHQW+DQGOLQJXSWR90UHDJHQWSRVLWLRQVZLWKUHIULJHUDWLRQ
TBIL Lp(a) *G6PD
》5HDFWLRQFXYHWWH80, optical diameter is 5 mm
DBIL Hcy ,J0
》,6(RSWLRQDO
TP *ApoA1 ,J$
Na ALB *ApoB ,J*
K *Ammonia *C3
CI *PA *C4
BiossaysTM 240 Plus
Ca *CHE *ACP
》7KURXJKSXW240 tests/hour
pH *AFU Cr(CREA) *Transferrin 》6DPSOH+DQGOLQJXSWR90 sample positions, STAT
Uric Acid
》5HDJHQW+DQGOLQJXSWR90UHDJHQWSRVLWLRQVZLWKUHIULJHUDWLRQ
Urea
》5HDFWLRQFXYHWWH80, optical diameter is 5 mm
*Cysc
Į$0< 》,6(RSWLRQDO
*mALB *Fe (Iron)
GLU 》:DVKLQJ6WDWLRQ: Available
*LIP Į0* *Ca
*LAC
ȕ0* *P (phos)
*HbA1c
0J BiossaysTM BC1200
* Available soon
》7KURXJKSXW600 tests/hour
》6DPSOH+DQGOLQJ115 sample positions, STAT
》5HDJHQW+DQGOLQJ2 trays, 90UHDJHQWSRVLWLRQV
ZLWKUHIULJHUDWLRQ
》5HDFWLRQFXYHWWH120, optical diameter is 6 mm
》,6(RSWLRQDO

BiossaysTM BC2200

》7KURXJKSXW1600 tests/hour
》6DPSOH+DQGOLQJ280 sample positions, STAT
》5HDJHQW+DQGOLQJ2 trays, 90UHDJHQWSRVLWLRQV
ZLWKUHIULJHUDWLRQ
》5HDFWLRQFXYHWWH330, optical diameter is 6 mm


 Biochemistry Biochemistry
Test Menu Analyzer
SPECIFICATION

CK TBA HDL-C *ASO

&.0% ALT (SGPT) LDL-C *RF
BiossaysTM 240
Į+%'+ AST (SGOT) TC *CRP )XOO5DQJH
》7KURXJKSXW240 tests/hour
LDH ALP TG *UIBC
》6DPSOH+DQGOLQJXSWR90 sample positions, STAT
*LDH1 GGT ApoE *Urine/CSF Protein
》5HDJHQW+DQGOLQJXSWR90UHDJHQWSRVLWLRQVZLWKUHIULJHUDWLRQ
TBIL Lp(a) *G6PD
》5HDFWLRQFXYHWWH80, optical diameter is 5 mm
DBIL Hcy ,J0
》,6(RSWLRQDO
TP *ApoA1 ,J$
Na ALB *ApoB ,J*
K *Ammonia *C3
CI *PA *C4
BiossaysTM 240 Plus
Ca *CHE *ACP
》7KURXJKSXW240 tests/hour
pH *AFU Cr(CREA) *Transferrin 》6DPSOH+DQGOLQJXSWR90 sample positions, STAT
Uric Acid
》5HDJHQW+DQGOLQJXSWR90UHDJHQWSRVLWLRQVZLWKUHIULJHUDWLRQ
Urea
》5HDFWLRQFXYHWWH80, optical diameter is 5 mm
*Cysc
Į$0< 》,6(RSWLRQDO
*mALB *Fe (Iron)
GLU 》:DVKLQJ6WDWLRQ: Available
*LIP Į0* *Ca
*LAC
ȕ0* *P (phos)
*HbA1c
0J BiossaysTM BC1200
* Available soon
》7KURXJKSXW600 tests/hour
》6DPSOH+DQGOLQJ115 sample positions, STAT
》5HDJHQW+DQGOLQJ2 trays, 90UHDJHQWSRVLWLRQV
ZLWKUHIULJHUDWLRQ
》5HDFWLRQFXYHWWH120, optical diameter is 6 mm
》,6(RSWLRQDO

BiossaysTM BC2200

》7KURXJKSXW1600 tests/hour
》6DPSOH+DQGOLQJ280 sample positions, STAT
》5HDJHQW+DQGOLQJ2 trays, 90UHDJHQWSRVLWLRQV
ZLWKUHIULJHUDWLRQ
》5HDFWLRQFXYHWWH330, optical diameter is 6 mm